Document is current
Any future updates will be listed below
-
Authors
Nishimura, Meiko https://orcid.org/0000-0002-7285-9426
Kogawa, Takahiro
Sugiyama, Keiji
Ozaki, Yukinori
Tanabe, Yuko
Funasaka, Chikako
Kurozumi, Sasagu
Yoshimura, Akiyo
Iwasa, Tsutomu
Sakai, Hitomi
Morita, Mitsunori
Watanabe, Satomi
Fujii, Takaaki
Yamamoto, Mitsugu
Tsuji, Yasushi
Terada, Mitsuo
Ota, Takayo
Tokunaga, Shinya
Shimokawa, Mototsugu
Takano, Toshimi
- License Information
-
More Information
Article History
Received: 30 March 2026
Accepted: 6 July 2026
First Online: 20 July 2026
Declarations
Competing interests: SK has received honoraria from Kyowa Kirin Co., Ltd., Daiichi-Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Pfizer Japan Inc. CF has received honoraria from Daiichi-Sankyo Co., Ltd., Eisai Co., Ltd., Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., MSD K.K., and Eli Lilly Japan K.K., and material from Daiichi-Sankyo Co., Ltd. YF has received honoraria from Eisai Co., Ltd., Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., MSD K.K., Chugai Pharmaceutical Co., Ltd., and Astellas Pharma Inc. AY has received honoraria from Pfizer Japan Inc., AstraZeneca K.K., and Chugai Pharmaceutical Co., Ltd. SW has received honoraria from Daiichi-Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., and Pfizer Japan Inc. TT has received honoraria from Daiichi-Sankyo Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, and MSD K.K. HS has received honoraria from Daiichi-Sankyo Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, AstraZeneca K.K., and Pfizer Japan Inc. HS has received research funding (outside of submitting work to her institution): Eli Lilly Japan K.K. YO has received honoraria from Eli Lilly Japan K.K., Pfizer Japan Inc., Daiichi-Sankyo Co., Ltd., and AstraZeneca K.K. TK has received grants from Eli Lilly Japan K.K., AstraZeneca K.K., Guardant Health, Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Be One, and Eisai Co., Ltd. TK has received consulting fees from Daiichi-Sankyo Co., Ltd., Astellas Pharma Inc., and received honoraria from Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Gilead Sciences, Astellas Pharma Inc., Eisai Co., Ltd., AstraZeneca K.K., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and MSD K.K. TK has received payment for expert testimony from Astellas Pharma Inc. TK has received support for attending meetings and/or travel from Pfizer Japan Inc., and Eisai Co., Ltd. TK has participated on a Data Safety Monitoring Board or Advisory Board from Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Gilead Sciences, OncoTherapy Science, Eisai Co., Ltd., Astra Zeneca K.K., Taiho Pharmaceutical Co., Ltd., and Be One. TK received equipment, materials, drugs, medical writing, gifts, and other services from Daiichi-Sankyo Co., Ltd. The other authors have no conflicts of interest.
